专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5728138A Cardiac defibrillator with multi-phase ferroelectric/antiferroelectric capacitor 失效
标题翻译：心脏除颤器与多相铁电/反铁电电容器
公开(公告)号：US5728138A
公开(公告)日：1998-03-17
申请号：US688883
申请日：1996-07-31
申请人： Joseph P. Dougherty , Kamau Wa Gachigi , Thomas R. Shrout , Sei-Joo Jang , Clive A. Randall , Philip M. Pruna
发明人： Joseph P. Dougherty , Kamau Wa Gachigi , Thomas R. Shrout , Sei-Joo Jang , Clive A. Randall , Philip M. Pruna
IPC分类号： A61N1/39
CPC分类号： A61N1/3956
摘要： A cardiac defibrillator includes a multilayer capacitor with a plurality of conductive electrodes and interspersed dielectric layers, each dielectric layer composed of constituents which cause it to exhibit an antiferroelectric phase. The constituents of each dielectric layer are such as to cause each layer to exhibit plural ferroelectric phases. The defibrillator includes a charging circuit for applying to the capacitor an electric field across each dielectric layer which causes a transition thereof through the plural ferroelectric phases. PLZT is the preferred dielectric material, at constituent values which cause the material to lie within the antiferroelectric phase and to exhibit plural ferroelectric phases.
摘要翻译：心脏除颤器包括具有多个导电电极和散布的电介质层的多层电容器，每个电介质层由使其呈现反铁电相的成分组成。每个电介质层的成分使得每层呈现多个铁电相。除颤器包括充电电路，用于向电容器施加横跨每个电介质层的电场，其导致其通过多个铁电相的转变。 PLZT是导致材料位于反铁电相内并呈现多个铁电相的成分值的优选介电材料。

2. 发明授权

US5993895A Method for reduction of sinter temperatures of antiferroelectric, lead-based ceramics by use of lithium compound additions and capacitors made with such ceramics 失效
标题翻译：通过使用锂化合物添加剂和由这种陶瓷制成的电容器来降低反铁电，铅基陶瓷的烧结温度的方法
公开(公告)号：US5993895A
公开(公告)日：1999-11-30
申请号：US949168
申请日：1997-10-10
申请人： Sei-Joo Jang , Joseph P. Dougherty , Wesley Hackenberger , MingFang Song , Steven Perini , Beth Jones
发明人： Sei-Joo Jang , Joseph P. Dougherty , Wesley Hackenberger , MingFang Song , Steven Perini , Beth Jones
IPC分类号： C04B35/491 , H01G4/12 , B05D3/02 , A61N1/39 , B05D1/36 , H01G4/06
CPC分类号： H01G4/1245 , C04B35/491 , Y10T29/43 , Y10T29/435
摘要： A method for densifying a dielectric antiferroelectric material includes the steps of adding a compound which includes lithium to the dielectric material to create a mixture thereof. Thereafter, the mixture is heated to a temperature of not greater than about 1100.degree. C. for a predetermined period to densify the mixture. It is preferred that the lithium compound be a lithium salt and that the dielectric material comprise a PLZT composition.
摘要翻译：一种用于致密化电介质反铁电材料的方法包括以下步骤：将包含锂的化合物添加到电介质材料中以产生其混合物。此后，将混合物加热至不超过约1100℃的温度一段预定时间以使混合物致密化。锂化合物优选为锂盐，并且电介质材料包含PLZT组合物。

3. 发明授权

US06169049A Solution coated hydrothermal BaTiO3 for low-temperature firing 失效
标题翻译：溶液涂层水热BaTiO3用于低温烧制
公开(公告)号：US06169049A
公开(公告)日：2001-01-02
申请号：US08847613
申请日：1997-04-28
申请人： John P. Witham , Clive A. Randall , Umesh Kumar , Ulagaraj Selvaraj , Sea-Fue Wang , Joseph P. Dougherty
发明人： John P. Witham , Clive A. Randall , Umesh Kumar , Ulagaraj Selvaraj , Sea-Fue Wang , Joseph P. Dougherty
IPC分类号： C04B35468
CPC分类号： C04B35/62222 , C04B35/468
摘要： Hydrothermal BaTiO3 crystallites were coated with Bismuth solutions prepared from Bismuth metal-organics and anhydrous solvents. The Bismuth metal-organics were Bi 2-ethylhexanoate and Bi-neodecanoate. Bismuth oxide was also used as a comparison to the Bismuth solutions. BaTiO3 ceramics with either 3.0 wt % equivalent Bismuth oxide or 5.0 wt % equivalent Bismuth oxide were made by sintering the compacts between 700° C. and 1000° C. BaTiO3 ceramics that were coated by Bi-neodecanoate densified >90% theoretical as low as 800° C. for 3.0 wt % equivalent Bi2O3. Average grain sizes of 0.2-0.4 &mgr;m were observed for Bi-coated BaTiO3 ceramics, for sintering temperatures below 950° C. Dielectric K versus temperature measurements of Bismuth-coated BaTiO3 ceramics, sintered in the lower temperature ranges, showed consistently superior dielectric characteristics.
摘要翻译：用由铋金属有机物和无水溶剂制备的铋溶液涂覆水热BaTiO 3微晶。铋金属有机物为Bi 2-乙基己酸酯和双 - 新癸酸酯。氧化铋也用作与铋溶液的比较。通过烧结700℃和1000℃之间的压块来制备具有3.0重量％当量氧化铋或5.0重量％当量氧化铋的BaTiO 3陶瓷。由新癸酸酯涂覆的BaTiO 3陶瓷致密化> 90％理论值低至 800℃，3.0重量％当量Bi 2 O 3。对于Bi包覆的BaTiO 3陶瓷，烧结温度低于950℃，观察到平均晶粒尺寸为0.2-0.4μm。在较低温度范围内烧结的铋包覆的BaTiO 3陶瓷的介电K与温度测量显示出一贯优异的介电特性。

4. 发明授权

US06376393B1 Method for producing anisotropic dielectric layer and devices including same 失效
标题翻译：各向异性介电层的制造方法及其制造方法
公开(公告)号：US06376393B1
公开(公告)日：2002-04-23
申请号：US09224044
申请日：1998-12-31
申请人： Mike Newton , Joseph P. Dougherty , Else Breval , Maria Klimkiewicz , Yi Ton Shi , Dean Arakaki
发明人： Mike Newton , Joseph P. Dougherty , Else Breval , Maria Klimkiewicz , Yi Ton Shi , Dean Arakaki
IPC分类号： H01L2131
CPC分类号： G06K9/00053 , A61B5/0531 , A61B5/1172
摘要： A method for making an anisotropic dielectric layer includes the steps of: forming a fluid layer comprising a plurality of magnetizable particles, for example, in a fluid capable of solidifying to fix the configuration of the magnetizable particles in a dielectric matrix; aligning the magnetizable particles of the fluid layer in a predetermined configuration by applying a magnetic field thereto; and fixing the aligned magnetizable particles in the predetermined configuration within the dielectric matrix by solidifying the fluid. In one particularly advantageous application, the fluid layer is coated onto a surface portion of an integrated circuit, such as a fingerprint sensor, to provide mechanical protection without effecting the image resolution. In addition, the step of aligning for certain devices preferably comprises aligning the magnetizable particles in a predetermined configuration so that an impedance perpendicular to the anisotropic dielectric layer is less than an impedance parallel to the anisotropic dielectric layer. The magnetizable particles may be mixed in a curable polymer fluid, and the step of fixing the aligned magnetizable particles may comprise curing the curable polymer fluid, such as by applying heat or radiation.
摘要翻译：制造各向异性介电层的方法包括以下步骤：形成包含多个可磁化颗粒的流体层，例如在能够固化的流体中，将可磁化颗粒的构型固定在电介质基质中; 通过向其施加磁场来将流体层的可磁化颗粒对准预定构造; 以及通过固化所述流体将所述对准的可磁化颗粒固定在所述电介质基质内的所述预定构型中。在一个特别有利的应用中，将流体层涂覆到诸如指纹传感器的集成电路的表面部分上，以提供机械保护而不影响图像分辨率。此外，对于某些装置的对准步骤优选地包括以预定构型对准可磁化颗粒，使得垂直于各向异性介电层的阻抗小于平行于各向异性介电层的阻抗。可磁化颗粒可以混合在可固化聚合物流体中，并且固定排列的可磁化颗粒的步骤可以包括固化可固化聚合物流体，例如通过施加热量或辐射。

5. 发明授权

US6043230A Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 有权
标题翻译：具有增加的口服生物利用度的抗病毒膦酰基甲氧基核苷酸类似物
公开(公告)号：US6043230A
公开(公告)日：2000-03-28
申请号：US314606
申请日：1999-05-19
申请人： Murty N. Arimilli , Kenneth C. Cundy , Joseph P. Dougherty , Choung U. Kim , Reza Oliyai , Valentino J. Stella
发明人： Murty N. Arimilli , Kenneth C. Cundy , Joseph P. Dougherty , Choung U. Kim , Reza Oliyai , Valentino J. Stella
IPC分类号： C07F9/6512 , C07F9/6561 , A61K31/675
CPC分类号： C07F9/65616 , C07F9/65121
摘要： Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure -OC(R.sup.2).sub.2 OC(O) X(R).sub.a, wherein R.sup.2 independently is H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR.sup.3 in which R.sup.3 is C.sub.1 -C12 alkyl; X is N or O; R is independently H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, axido, nitro, --O--, --N.dbd., --NR.sup.4 --, --N(R.sup.4).sub.2 -- or OR.sup.3, R.sup.4 independently is --H or C.sub.1 -C.sub.8 alkyl, provided that at least one R is not H; and a is 1 or 2, with the proviso that when a is 2 and X is N, (a) two R groups can be taken together to form a carbocycle or oxygen-containing heterocycle, or (b) one R additionally can be OR.sup.3. The compounds are useful as intermediates for the preparation of antiviral compounds or oligonucleotides, or are useful for administration directly to patients for antiviral therapy or prophylaxis. Embodiments are particularly useful when administered orally.
摘要翻译：提供新的化合物，其包含抗病毒膦基甲氧基核苷酸类似物与具有结构-OC（R 2）2 OC（O）X（R）a的碳酸酯和/或氨基甲酸酯的酯，其中R2独立地为H，C1-C12烷基，芳基，烯基炔基，烷基芳基，炔基芳基，烷芳基，芳基炔基，芳基烯基或芳烷基，其未被取代或被卤素，叠氮基，硝基或OR 3取代，其中R 3是C 1 -C 12烷基; X为N或O; R是独立的H，C 1 -C 12烷基，芳基，烯基，炔基，链烯基芳基，炔基芳基，烷芳基，芳基炔基，芳基烯基或芳基烷基，其未被取代或被卤素，轴酰基，硝基，-O - ， - N = - ， - N（R4）2-或OR3，R4独立地是-H或C1-C8烷基，条件是至少一个R不是H; 和a为1或2，条件是当a为2且X为N时，（a）两个R基团可以一起形成碳环或含氧杂环，或（b）一个R另外可以是OR 3 。该化合物可用作制备抗病毒化合物或寡核苷酸的中间体，或可用于直接给患者施用抗病毒治疗或预防。当口服给药时，实施方案特别有用。

6. 再颁专利

USRE38333E1 Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 有权
标题翻译：具有增加的口服生物利用度的抗病毒膦酰基甲氧基核苷酸类似物
公开(公告)号：USRE38333E1
公开(公告)日：2003-11-25
申请号：US10159888
申请日：2002-05-29
申请人： Murty N. Arimilli , Kenneth C. Cundy , Joseph P. Dougherty , Choung U. Kim , Reza Oliyai , Valentino J. Stella
发明人： Murty N. Arimilli , Kenneth C. Cundy , Joseph P. Dougherty , Choung U. Kim , Reza Oliyai , Valentino J. Stella
IPC分类号： C07F96512
CPC分类号： C07F9/65616 , C07F9/6512
摘要： Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure —OC(R2)2OC(O)X(R)a, wherein R2 independently is H, C1-C12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR3 in which R3 is C1-C12 alkyl; X is N or O; R is independently H, C1-C12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro, —O—, —N═, —NR4—, —N(R4)2— or OR3, R4 independently is —H or C1-C8 alkyl, provided that at least one R is not H; and a is 1 or 2, with the proviso that when a is 2 and X is N, (a) two R groups can be taken together to form a carbocycle or oxygen-containing heterocycle, or (b) one R additionally can be OR3. The compounds are useful as intermediates for the preparation of antiviral compounds or oligonucleotides, or are useful for administration directly to patients for antiviral therapy of prophylaxis. Embodiments are particularly useful when administered orally.

7. 发明授权

US6022714A Methods for attachment of a polynucleotide to a preselected material 失效
标题翻译：将多核苷酸连接到预选材料的方法
公开(公告)号：US6022714A
公开(公告)日：2000-02-08
申请号：US574860
申请日：1995-12-19
申请人： Eugene L. Brown , Joseph P. Dougherty , Mary Collins
发明人： Eugene L. Brown , Joseph P. Dougherty , Mary Collins
IPC分类号： C07B61/00 , C07H21/00 , C12Q1/68 , C07H21/02 , C07H21/04 , C12P19/34
CPC分类号： C07H21/00 , C12Q1/6834 , C07B2200/11 , C40B40/00 , Y10S435/81
摘要： Compositions and methods for selectively linking a polynucleotide through its 5' or 3' end to one or more preselected materials such as insoluble matrices, solid supports, proteins, small molecular or labels are disclosed. Use of these compositions and methods in the production of diagnostic and affinity reagents are also disclosed.
摘要翻译：公开了将多核苷酸通过其5'或3'端选择性连接到一种或多种预选物质如不溶性基质，固体支持物，蛋白质，小分子或标记物的组合物和方法。还公开了这些组合物和方法在制备诊断和亲和试剂中的用途。

8. 发明授权

US5545184A Cardiac defibrillator with high energy storage antiferroelectric capacitor 失效
标题翻译：心脏除颤器与高储能反铁电电容器
公开(公告)号：US5545184A
公开(公告)日：1996-08-13
申请号：US423500
申请日：1995-04-19
申请人： Joseph P. Dougherty
发明人： Joseph P. Dougherty
IPC分类号： A61N1/39
CPC分类号： A61N1/3956
摘要： A cardiac defibrillator which incorporates the invention hereof includes a multilayer capacitor with a plurality of conductive electrodes and interspersed dielectric layers, each dielectric layer composed of constituents which cause the dielectric layer to exhibit antiferroelectric characteristics. The defibrillator includes a charging circuit for applying to the capacitor an electric field across each dielectric layer that is at least equal to E.sub.f, where E.sub.f is a field value that enables the dielectric layer to transition to a ferroelectric phase. A preferred dielectric material comprises lead, lanthanum, zirconium and titanium, all at constituent values which cause the resulting ceramic material to lie within the antiferroelectric region.
摘要翻译：结合本发明的心脏除颤器包括具有多个导电电极和散布电介质层的多层电容器，每个电介质层由使电介质层显示出反铁电特性的成分组成。除颤器包括充电电路，用于向电容器施加横跨每个电介质层的至少等于Ef的电场，其中Ef是使电介质层能够转变到铁电相的场值。一种优选的电介质材料包括铅，镧，锆和钛，全部以导致所得陶瓷材料位于反铁电区内的成分值。

9. 发明授权

US6069249A Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 有权
标题翻译：具有增加的口服生物利用度的抗病毒膦酰基甲氧基核苷酸类似物
公开(公告)号：US6069249A
公开(公告)日：2000-05-30
申请号：US314607
申请日：1999-05-19
申请人： Murty N. Arimilli , Kenneth C. Cundy , Joseph P. Dougherty , Choung U. Kim , Reza Oliyai , Valentino J. Stella
发明人： Murty N. Arimilli , Kenneth C. Cundy , Joseph P. Dougherty , Choung U. Kim , Reza Oliyai , Valentino J. Stella
IPC分类号： C07F9/6512 , C07F9/6561
CPC分类号： C07F9/65616 , C07F9/65121
摘要： Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure --OC(R.sup.2).sub.2 OC(O)X(R).sub.a, wherein R.sup.2 independently is H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR.sup.3 in which R.sup.3 is C.sub.1 -C.sub.12 alkyl; X is N or O; R is independently H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro, --O--, --N.dbd., --NR.sup.4 --, --N(R.sup.4).sub.2 -- or OR.sup.3, R.sup.4 independently is --H or C.sub.1 -C.sub.8 alkyl, provided that at least one R is not H; and a is 1 or 2, with the proviso that when a is 2 and X is N, (a) two R groups can be taken together to form a carbocycle or oxygen-containing heterocycle, or (b) one R additionally can be OR.sup.3. The compounds are useful as intermediates for the preparation of antiviral compounds or oligonucleotides, or are useful for administration directly to patients for antiviral therapy of prophylaxis. Embodiments are particularly useful when administered orally.
摘要翻译：提供新的化合物，其包含抗病毒膦基甲氧基核苷酸类似物与具有结构-OC（R 2）2 OC（O）X（R）a的碳酸酯和/或氨基甲酸酯的酯，其中R2独立地为H，C1-C12烷基，芳基，烯基炔基，烷基芳基，炔基芳基，烷芳基，芳基炔基，芳基烯基或芳烷基，其未被取代或被卤素，叠氮基，硝基或OR 3取代，其中R 3是C 1 -C 12烷基; X为N或O; R是独立的H，C 1 -C 12烷基，芳基，烯基，炔基，链烯基芳基，炔基芳基，烷芳基，芳基炔基，芳基烯基或芳烷基，其未被取代或被卤素，叠氮基，硝基，-O - ， - N = - ， - N（R4）2-或OR3，R4独立地是-H或C1-C8烷基，条件是至少一个R不是H; 和a为1或2，条件是当a为2且X为N时，（a）两个R基团可以一起形成碳环或含氧杂环，或（b）一个R另外可以是OR 3 。该化合物可用作制备抗病毒化合物或寡核苷酸的中间体，或者可用于直接给患者预防用于抗病毒治疗的患者。当口服给药时，实施方案特别有用。

10. 发明授权

US5977089A Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 有权
标题翻译：具有增加的口服生物利用度的抗病毒膦酰基甲氧基核苷酸类似物
公开(公告)号：US5977089A
公开(公告)日：1999-11-02
申请号：US187763
申请日：1998-11-06
申请人： Murty N. Arimilli , Kenneth C. Cundy , Joseph P. Dougherty , Choung U. Kim , Reza Oliyai , Valentino J. Stella
发明人： Murty N. Arimilli , Kenneth C. Cundy , Joseph P. Dougherty , Choung U. Kim , Reza Oliyai , Valentino J. Stella
IPC分类号： C07F9/6512 , C07F9/6561 , A61K31/675
CPC分类号： C07F9/65616 , C07F9/65121
摘要： Compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure --OC(R.sup.2).sub.2 OC(O)X(R).sub.a, wherein R.sup.2 independently is H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR.sup.3 in which R.sup.3 is C.sub.1 -C.sub.12 alkyl; X is N or O; R is independently H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro, --O--, --N.dbd., --NR.sup.4 --, --N(R.sup.4).sub.2 -- or OR.sup.3, R.sup.4 independently is --H or C.sub.1 -C.sub.8 alkyl, provided that at least one R is not H; and a is 1 or 2, with the proviso that when a is 2 and X is N, (a) two R groups can be taken together to form a carbocycle or oxygen-containing heterocycle, or (b) one R additionally can be OR.sup.3. The compounds are useful as intermediates for the preparation of antiviral compounds or oligonucleotides, or are useful for administration directly to patients for antiviral therapy or prophylaxis. Embodiments are particularly useful when administered orally.
摘要翻译：提供了包含具有结构-OC（R 2）2 OC（O）X（R）a的碳酸酯和/或氨基甲酸酯的抗病毒膦基甲氧基核苷酸类似物的酯的化合物，其中R2独立地是H，C1-C12烷基，芳基，烯基，炔基，烷基芳基，炔基芳基，烷芳基，芳基炔基，芳基烯基或芳基烷基，其未被取代或被卤素，叠氮基，硝基或OR 3取代，其中R 3是C 1 -C 12烷基; X为N或O; R是独立的H，C 1 -C 12烷基，芳基，烯基，炔基，链烯基芳基，炔基芳基，烷芳基，芳基炔基，芳基烯基或芳烷基，其未被取代或被卤素，叠氮基，硝基，-O - ， - N = - ， - N（R4）2-或OR3，R4独立地是-H或C1-C8烷基，条件是至少一个R不是H; 和a为1或2，条件是当a为2且X为N时，（a）两个R基团可以一起形成碳环或含氧杂环，或（b）一个R另外可以是OR 3 。该化合物可用作制备抗病毒化合物或寡核苷酸的中间体，或可用于直接给患者施用抗病毒治疗或预防。当口服给药时，实施方案特别有用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式